Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis

PURPOSE: Achievement of deep molecular response with a tyrosine kinase inhibitor in patients with chronic myeloid leukemia (CML) is required to attempt discontinuation of therapy in these patients. The current subanalysis from the Evaluating Nilotinib Efficacy and Safety in Clinical Trials as First-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Cancer Res Clin Oncol
Main Authors: Giles, Francis J., Rea, Delphine, Rosti, Gianantonio, Cross, Nicholas C. P., Steegmann, Juan Luis, Griskevicius, Laimonas, le Coutre, Philipp, Coriu, Daniel, Petrov, Ljubomir, Ossenkoppele, Gert J., Mahon, Francois-Xavier, Saussele, Susanne, Hellmann, Andrzej, Koskenvesa, Perttu, Brümmendorf, Tim H., Gastl, Gunther, Castagnetti, Fausto, Vincenzi, Beatrice, Haenig, Jens, Hochhaus, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2017
Assuntos:
Original Article – Clinical Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5504128/
https://ncbi.nlm.nih.gov/pubmed/28364360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-017-2402-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados